David Tretheway, Ashok Jain, Randi LaPoint, Rajeev Sharma, Mark Orloff, Patricia Milot, Adel Bozorgzadeh, Charlotte Ryan – 6 March 2008 – Recurrent hepatitis C is virtually universal after liver transplantation; however, an individual patient's clinical course and disease burden are highly variable and difficult to predict. The fibrosis score determined on posttransplant biopsies appears to be a sensitive and specific marker of disease progression and severity.

Irene J. Lo, Jay H. Lefkowitch, Nikki Feirt, Barbara Alkofer, Cindy Kin, Benjamin Samstein, James V. Guarrera, John F. Renz – 6 March 2008 – Extended‐donor criteria (EDC) liver allografts potentiate the role of procurement biopsy in organ utilization. To expedite allocation, histologic evaluation is routinely performed upon frozen‐section (FS) specimens by local pathologists.

Yu Bai, Jun Gao, Duo‐Wu Zou, Zhao‐Shen Li – 6 March 2008

Ira M. Jacobson, Robert S. Brown – 6 March 2008

Florian Bihl, Elisabetta Loggi, John V. Chisholm, Maurizio Biselli, Maria C. Morelli, Carmela Cursaro, Norah A. Terrault, Mauro Bernardi, Antonio Bertoletti, Pietro Andreone, Christian Brander – 6 March 2008 – Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is associated with poor graft‐ and patient‐survival. Treatment with HBV‐specific immunoglobulins (HBIG) in combination with nucleos(t)ide analogs is effective in preventing HBV reinfection of the graft and improving OLT outcome.

Michael A. Zimmerman, James F. Trotter, Michael Wachs, Tom Bak, Jeffrey Campsen, Afshin Skibba, Igal Kam – 6 March 2008 – Experience with sirolimus (SRL)‐based immunosuppression following orthotopic liver transplantation (OLT) is rapidly accumulating. In combination with calcineurin inhibitors (CNIs), SRL may reduce the incidence of acute rejection and lower overall required drug levels. This study sought to quantify long‐term outcome following OLT in patients with cirrhosis and concomitant hepatocellular carcinoma (HCC) who were treated with an SRL‐based regimen as a primary therapy.

Jinlin Hou, Nathaniel Brown, JiDong Jia – 5 March 2008

Resat Ozaras, Hakan Leblebicioglu, Cafer Eroglu – 5 March 2008

Tracy Swan, Raymond T. Chung – 5 March 2008

Siew Chin Ong, Belinda Mak, Myat Oo Aung, Shu‐Chuen Li, Seng‐Gee Lim – 3 March 2008 – The relationship between stages of chronic hepatitis B liver disease and health‐related quality of life (HRQoL) is an important aspect of the overall management of hepatitis B virus (HBV) infection, yet is not well characterized. Consequently we sought to examine HRQoL in HBV patients, stratified by disease severity, compared with normal controls and hypertensive patients, using the Short Form 36 Health Survey (SF‐36) and the EQ‐5D self‐report questionnaire.